Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma

Trial Profile

A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma

Status: Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary) ; Vocimagene amiretrorepvec-flucytosine gene therapy (Primary) ; Temozolomide
  • Indications Anaplastic astrocytoma; Glioblastoma; Oligodendroglioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2019 According to an Tocagen media release, this study will be presented at the 24th Annual Meeting of the Society for Neuro-Oncology (SNO).
    • 24 Sep 2019 Status changed from planning to not yet recruiting.
    • 08 Aug 2019 According to a Tocagen media release, the company has submitted a draft protocol to FDA for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top